Veronese Federica, Seoni Silvia, Tarantino Vanessa, Buttafava Matteo, Airoldi Chiara, Meiburger Kristen M, Zavattaro Elisa, Savoia Paola
SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy.
Biolab, PolitoBIOMed Lab, Department of Electronics and Telecommunications, Politecnico di Torino, Turin, Italy.
Front Med (Lausanne). 2022 Sep 7;9:987696. doi: 10.3389/fmed.2022.987696. eCollection 2022.
The high incidence of actinic keratoses among both the elderly population and immunocompromised subjects and the considerable risk of progression from to invasive neoplasms makes it essential to identify new prevention, treatment, and monitoring strategies.
The aim of this study was to evaluate the efficacy on AKs of a topical product (Rilastil AK Repair 100 +) containing high-protection sunscreens, a DNA Repair Complex with antioxidant and repairing action against UV-induced DNA damage, and nicotinamide, a water-soluble derivative of vitamin B3 that demonstrated several photoprotective effects both and .
The study enrolled 74 Caucasian patients, which included 42 immunocompetent and 32 immunosuppressed subjects. The efficacy of the treatment has been evaluated through the clinical index AKASI score and the non-invasive Near-Infrared Spectroscopy method.
The AKASI score proved to be a valid tool to verify the efficacy of the product under study, highlighting an average percentage reduction at the end of treatment of 31.37% in immunocompetent patients and 22.76% in organ transplant recipients, in comparison to the initial values, with a statistically significant reduction also in the single time intervals (T0 vs. T1 and T1 vs. T2) in both groups. On the contrary, the Near-Infrared Spectroscopy (a non-invasive technique that evaluates hemoglobin relative concentration variations) did not find significant differences for OHb and HHb signals before and after the treatment, probably because the active ingredients of the product under study can repair the photo-induced cell damage, but do not significantly modify the vascularization of the treated areas.
The results deriving from this study demonstrate the efficacy of the product under study, confirming the usefulness of the AKASI score in monitoring treated patients. Near-Infrared Spectroscopy could represent an interesting strategy for AK patients monitoring, even if further large-scale studies will be needed.
光化性角化病在老年人群和免疫功能低下的人群中发病率较高,且从光化性角化病发展为侵袭性肿瘤的风险相当大,因此确定新的预防、治疗和监测策略至关重要。
本研究旨在评估一种局部用产品(丽蕾克AK修复100+)对光化性角化病的疗效,该产品含有高防护性防晒剂、具有抗氧化作用且能修复紫外线诱导的DNA损伤的DNA修复复合物,以及烟酰胺(维生素B3的水溶性衍生物,已证明其在体内和体外均具有多种光保护作用)。
该研究招募了74名白种人患者,其中包括42名免疫功能正常者和32名免疫抑制者。通过临床指标AKASI评分和非侵入性近红外光谱法评估治疗效果。
AKASI评分被证明是验证所研究产品疗效的有效工具,与初始值相比,免疫功能正常患者在治疗结束时平均降低百分比为31.37%,器官移植受者为22.76%,两组在各个时间间隔(T0与T1以及T1与T2)均有统计学意义的显著降低。相反,近红外光谱法(一种评估血红蛋白相对浓度变化的非侵入性技术)在治疗前后未发现氧合血红蛋白(OHb)和脱氧血红蛋白(HHb)信号有显著差异,可能是因为所研究产品的活性成分可修复光诱导的细胞损伤,但不会显著改变治疗区域的血管化情况。
本研究结果证明了所研究产品的疗效,证实了AKASI评分在监测接受治疗患者方面的有用性。近红外光谱法可能是监测光化性角化病患者的一种有前景的策略,尽管还需要进一步的大规模研究。